Western blotting was performed using a standard protocol. We used the following primary and secondary antibodies:
PCNA (1:1000;
ab92552, Abcam, Cambridge, MA, USA),
CYCLIN D1 (1:1000; #55506, Cell Signaling Technology, Danvers, MA, USA), phospho-CDK2 (p-CDK2; 1:1000; #2561, Cell Signaling Technology, Danvers, MA, USA), CDK2 (1:1000; #18048, Cell Signaling Technology, Danvers, MA, USA),
SIRT1 (1:1000; #9475, Cell Signaling Technology, Danvers, MA, USA), PGC1α (1:1000; NAP1-04676, Novus Biologicals, Littleton, CO, USA), NRF1 (1:1000; #46743, Cell Signaling Technology),
mtTFA (1:1000;
ab131607, Abcam, Cambridge, MA, USA), ACTIN (1:2000;
sc-8432, Santa Cruz Biotechnology, Dallas, TX, USA), ACTB (1:2000; A5316),
HRP-conjugated anti-rabbit IgG (1:5000; #65-6120, Invitrogen, Carlsbad, CA, USA) and
anti-IgG (1:5000; #62-6520, Invitrogen, Carlsbad, CA, USA). Bands were detected using a
ChemiDoc XRD+ system (Bio-Rad, Hercules, CA, USA), and relative intensity was assessed using
Image Lab software (Bio-Rad, Hercules, CA, USA).
Kim K.H, & Lee K.A. (2022). Metabolic Rewiring by Human Placenta-Derived Mesenchymal Stem Cell Therapy Promotes Rejuvenation in Aged Female Rats. International Journal of Molecular Sciences, 23(1), 566.